Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
Page standards status: Informative |
Generated Narrative: Citation 179631
version: 10; Last updated: 2025-03-27 12:25:43+0000
Profile: JournalArticleCitation
identifier: FEvIR Object Identifier/https://fevir.net/FOI/179631, https://pubmed.ncbi.nlm.nih.gov
/19029421, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.44
version: 1.0.0-ballot2
title: 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
status: Active
date: 2025-03-27 17:53:24+0000
publisher: HL7 International / Clinical Decision Support
contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss
description:
This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.
Code | Value[x] |
Citation Classification Type fevir-platform-use: FEvIR Platform Use | Medline Base |
jurisdiction: World
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
approvalDate: 2009-01-13
lastReviewDate: 2023-02-02
author: Computable Publishing®: MEDLINE-to-FEvIR Converter:
classification
type: Citation Source
classifier: MEDLINE
classification
type: MEDLINE Citation Owner
classifier: National Library of Medicine, Index Section
currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish
statusDate
activity: PubMed Pubstatus of Pubmed
period: ?? --> 2008-11-26 09:00:00+0000
statusDate
activity: PubMed Pubstatus of Medline
period: ?? --> 2009-01-14 09:00:00+0000
statusDate
activity: PubMed Pubstatus of Entrez
period: ?? --> 2008-11-26 09:00:00+0000
statusDate
activity: PubMed Pubstatus of PMC release
period: ?? --> 2009-12-20
citedArtifact
identifier:
https://pubmed.ncbi.nlm.nih.gov
/19029421,https://www.ncbi.nlm.nih.gov/pmc/
/PMC3864402,https://doi.org
/10.1200/JCO.2007.15.9830, pii/JCO.2007.15.9830Titles
Type Language Text Primary title English Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
Abstracts
Type Text Primary human use PURPOSE: We conducted a phase III trial in patients with previously untreated metastatic prostate cancer to test the hypothesis that three 8-week cycles of ketoconazole and doxorubicin alternating with vinblastine and estramustine, given in addition to standard androgen deprivation, would delay the appearance of castrate-resistant disease. PATIENTS AND METHODS: Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy. The primary end point was time to castrate-resistant progression as shown by increasing prostate-specific antigen, new radiographic lesions, worsening cancer-related symptoms, or receipt of any other systemic therapy. RESULTS: Three hundred six patients were registered; 286 are reported. Median time to progression was 24 months (95% CI, 18 to 39 months) in the standard therapy arm, and 35 months (95% CI, 26 to 44 months) in the chemohormonal group (P = .39). At median follow-up of 6.4 years, overall survival was 5.4 years (95% CI, 4.7 to 7.8 years) in the standard therapy arm versus 6.1 years (95% CI, 5.1 to 10.1 years; P = .41). Prostate-specific antigen kinetics at the time of androgen ablation and the nadir after hormone treatment were strongly correlated with survival. Chemotherapy significantly increased the burden of therapy, with 51% of patients experiencing an adverse event of grade 3 or worse, especially thromboembolic events. CONCLUSION: There is no role for ketoconazole and doxorubicin alternating with vinblastine and estramustine before emergence of a castrate-resistant phenotype.
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/17237035/
type: cites
classifier: Journal Article
citation:
Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2007. CA Cancer J Clin 57:43-66, 2007
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/7679039/
type: cites
classifier: Journal Article
citation:
Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109, 1993
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/11027418/
type: cites
classifier: Journal Article
citation:
Beer T, Raghavan D: Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder. Prostate 45:184-193, 2000
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/9815636/
type: cites
classifier: Journal Article
citation:
Ellerhorst JA, Tu SM, Amato RJ, et al: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3:2371-2376, 1997
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/10561202/
type: cites
classifier: Journal Article
citation:
Smith DC, Esper P, Strawderman M, et al: Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664-1671, 1999
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/11134194/
type: cites
classifier: Journal Article
citation:
Kelly WK, Curley T, Slovin S, et al: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19:44-53, 2001
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/12610188/
type: cites
classifier: Journal Article
citation:
Millikan RE, Thall PF, Lee SJ, et al: Randomized multicenter phase II trial of two multicomponent regimens in androgen independent prostate cancer. J Clin Oncol 21:878-883, 2003
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/15470214/
type: cites
classifier: Journal Article
citation:
Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/15470213/
type: cites
classifier: Journal Article
citation:
Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/6337697/
type: cites
classifier: Journal Article
citation:
Murphy GP, Beckley S, Brady MF, et al: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51:1264-1272, 1983
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/3523938/
type: cites
classifier: Journal Article
citation:
Murphy GP, Huben RP, Priore R: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28:36-40, 1986
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/2213104/
type: cites
classifier: Journal Article
citation:
Osborne CK, Blumenstein B, Crawford ED, et al: Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: Final results of a randomized Southwest Oncology Group study. J Clin Oncol 8:1675-1682, 1990
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/9267791/
type: cites
classifier: Journal Article
citation:
Pummer K, Lehnert M, Stettner H, et al: Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32:81-85, 1997. (suppl)
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/9123707/
type: cites
classifier: Journal Article
citation:
Janknegt RA, Boon TA, van de Beek C, et al: Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. Urology 49:411-420, 1997
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/9619712/
type: cites
classifier: Journal Article
citation:
Fontana D, Bertetto O, Fasolis G, et al: Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 84:39-44, 1998
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/10472324/
type: cites
classifier: Journal Article
citation:
Boel K, Van Poppel H, Goethuys H, et al: Mitomycin C for metastatic prostate cancer: Final analysis of a randomized trial. Anticancer Res 19:2157-2161, 1999
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/10524892/
type: cites
classifier: Journal Article
citation:
de Reijke TM, Keuppens FI, Whelan P, et al: Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: The final results of a European organization for research in cancer therapy genitourinary group trial. J Urol 162:1658-1664, 1999
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/11256836/
type: cites
classifier: Journal Article
citation:
Kuriyama M, Takanhashi Y, Sahashi M, et al: Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol 31:18-24, 2001
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/14706014/
type: cites
classifier: Journal Article
citation:
Noguchi M, Noda Shinshi, Yoshida M, et al: Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 11:103-109, 2004
relatesTo
type: cites
citation:
Fisher LD, Belle GV: Biostatistics: A Methodology For the Health Sciences. New York, NY, John Wiley, 1993
relatesTo
type: cites
citation:
Randles RH, Wolfe DA: Introduction to the Theory of Nonparametric Statistics. New York, NY, John Wiley, 1979
relatesTo
type: cites
citation:
Lawless JF: Statistical Models and Methods for Lifetime Data. New York, NY, John Wiley, 1982
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/16921051/
type: cites
classifier: Journal Article
citation:
Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from the Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 24:3984-3990, 2006
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/16170163/
type: cites
classifier: Journal Article
citation:
Stewart AJ, Scher HI, Chen M-H, et al: Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23:6556-6560, 2005
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/10694556/
type: cites
classifier: Journal Article
citation:
Pettaway CA, Pisters LL, Troncoso P, et al: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 18:1050-1057, 2000
relatesTo
TargetUri: https://pubmed.ncbi.nlm.nih.gov/18207190/
type: cites
classifier: Journal Article
citation:
Friedman J, Dunn RL, Wood D, et al: Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 179:911-916, 2008
publicationForm
publishedIn
type: Periodical
identifier: Electronic ISSN Type/1527-7755, ISOAbbreviation/J Clin Oncol, ISSN Linking/0732-183X, Medline Title Abbreviation/J Clin Oncol, NLM Unique ID/8309333
title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
publisherLocation: United States
citedMedium: Internet
volume: 26
issue: 36
articleDate: 2008-12-20
publicationDateText: 2008-Dec-20
pageString: 5936-42
publicationForm
citedMedium: Internet without issue
articleDate: 2008-11-24
webLocation
classifier: Abstract
webLocation
classifier: DOI Based
classification
type: Publishing Model
classifier: Print Electronic
classification
type: Chemical
classifier: Androgen Antagonists, Antibiotics, Antineoplastic, Antineoplastic Agents, Alkylating, Antineoplastic Agents, Phytogenic, Estramustine, Vinblastine, Doxorubicin, Ketoconazole
classification
type: MeSH heading
artifactAssessment: ArtifactAssessment: artifact[x] = this resource
classification
type: Publication type
classifier: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial
classification
type: Knowledge Artifact Type
classifier: Journal Article
artifactAssessment: Classifier added by Computable Publishing LLC
classification
type: Citation subset
classifier: IM
contributorship
complete: true
entry
contributor: Millikan RE
forenameInitials: RE
affiliation: Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Pressler, CPB7.3462, Houston, TX 77030, USA. rmillika@mdanderson.org
entry
contributor: Wen S
forenameInitials: S
entry
contributor: Pagliaro LC
forenameInitials: LC
entry
contributor: Brown MA
forenameInitials: MA
entry
contributor: Moomey B
forenameInitials: B
entry
contributor: Do KA
forenameInitials: KA
entry
contributor: Logothetis CJ
forenameInitials: CJ
Generated Narrative: Practitioner #contributor0
name: Randall E Millikan
Generated Narrative: Practitioner #contributor1
name: Sijin Wen
Generated Narrative: Practitioner #contributor2
name: Lance C Pagliaro
Generated Narrative: Practitioner #contributor3
name: Melissa A Brown
Generated Narrative: Practitioner #contributor4
name: Brenda Moomey
Generated Narrative: Practitioner #contributor5
name: Kim-Anh Do
Generated Narrative: Practitioner #contributor6
name: Christopher J Logothetis
Generated Narrative: ArtifactAssessment #meshHeading0
content
type: components (if present) include qualifier codings
classifier: Adult
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Aged
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Aged, 80 and over
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Androgen Antagonists
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: therapeutic use
Components
Type Classifier is Major topic Yes content
type: components (if present) include qualifier codings
classifier: Antibiotics, Antineoplastic
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
Type Classifier is Major topic No content
type: components (if present) include qualifier codings
classifier: Antineoplastic Agents, Alkylating
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
Type Classifier is Major topic No content
type: components (if present) include qualifier codings
classifier: Antineoplastic Agents, Phytogenic
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
Type Classifier is Major topic No content
type: components (if present) include qualifier codings
classifier: Antineoplastic Combined Chemotherapy Protocols
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: therapeutic use
Components
Type Classifier is Major topic Yes content
type: components (if present) include qualifier codings
classifier: Doxorubicin
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
Type Classifier is Major topic No content
type: components (if present) include qualifier codings
classifier: Estramustine
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
Type Classifier is Major topic No content
type: components (if present) include qualifier codings
classifier: Humans
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Ketoconazole
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
Type Classifier is Major topic No content
type: components (if present) include qualifier codings
classifier: Male
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Middle Aged
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Neoplasm Metastasis
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Prostatic Neoplasms
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: drug therapy
Components
Type Classifier is Major topic Yes component
type: qualifier
classifier: mortality
Components
Type Classifier is Major topic No content
type: components (if present) include qualifier codings
classifier: Vinblastine
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
Type Classifier is Major topic No